Aligos Therapeutics, Inc. (ALGS)

Market Cap	47.88M
Revenue (ttm)	n/a
Net Income (ttm)	-96.05M
Shares Out	42.94M
EPS (ttm)	-2.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,056
Open	1.14
Previous Close	1.11
Day's Range	1.06 - 1.19
52-Week Range	0.84 - 2.41
Beta	2.50
Analysts	Buy
Price Target	4.08 (+265.92%)
Earnings Date	May 2, 2023

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secreti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: ALGS

Analyst Forecast

According to 11 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is $4.08, which is an increase of 265.92% from the latest price.

Price Target

$4.08

(265.92% upside)

Analyst Consensus: Buy